Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats., PMID:40513507
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029
Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer., PMID:40484776
Treatment of breast cancer in a patient with sickle cell disease., PMID:40484435
Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis., PMID:40466817
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers., PMID:40443068
Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models., PMID:40437743
Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients., PMID:40437155
Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer., PMID:40437017
Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report., PMID:40433060
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine., PMID:40428777
HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis., PMID:40426980
T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective., PMID:40405946
T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects., PMID:40402389
Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience., PMID:40380283
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer., PMID:40374836
Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran., PMID:40365303
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan., PMID:40349141
Successful Neoadjuvant Treatment Using Trastuzumab Emtansine (Kadcyla) for Locally Advanced and Metastatic Lacrimal Gland Adenocarcinoma., PMID:40334147
Enhanced cytotoxicity of T-DM1 in HER2-low carcinomas via autophagy inhibition., PMID:40315224
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies., PMID:40304863
The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases., PMID:40297622
Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan., PMID:40295416
Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
Therapy of early breast cancer: current status and perspectives., PMID:40261372
Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study., PMID:40255472
Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer., PMID:40242965
Response to Michelerio et al regarding "Antibody-drug conjugates: A review of cutaneous adverse effects"., PMID:40239815
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing., PMID:40201309
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study., PMID:40192324
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908
A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas., PMID:40170861
Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study., PMID:40166653
CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance., PMID:40165206
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study., PMID:40162996
Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study., PMID:40161117
Microfluidic organoid-slice-on-a-chip system for studying anti-cholangiocarcinoma drug efficacy and hepatorenal toxicity., PMID:40152597
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy., PMID:40148195
Effects of trastuzumab emtansine on canine osteosarcoma cells., PMID:40128930
A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972
Antibody-drug conjugates in breast cancer: current evidence and future directions., PMID:40114224
Stability of intravenous antibody dilutions in clinical use: Differences across patient populations with varying body weights., PMID:40112902
Mirvetuximab soravtansine: current and future applications., PMID:40102896
New treatment options for generalized HER2-positive breast cancer in higher-line systemic palliative therapy., PMID:40088439
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer., PMID:40051118
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report., PMID:40050918
For research use only. Not for human or drug use.
